InflaRx (IFRX) EBIT Margin (2018 - 2026)
InflaRx (IFRX) posted EBIT Margin of 450.39% for Q1 2026, up 513.19% sequentially from 73.45% in Q4 2025, and up 3653868.0% YoY from N/an in Q1 2025.
InflaRx (IFRX) EBIT Margin (2018 - 2026) Analysis & Trends
InflaRx has reported EBIT Margin for 9 years, with the latest figure at 450.39% in Q1 2026.
- Quarterly EBIT Margin rose 3653868.0% year-over-year to 450.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.01% (up 1463.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
- EBIT Margin advanced to 450.39% in Q1 2026 per IFRX's latest filing, from 73.45% in the prior quarter.
- Over five years, EBIT Margin peaked at 1785.36% in Q1 2022 and troughed at 242200.14% in Q2 2024.
- A 5-year average of 23291.42% and a median of 7.31% in 2022 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin sank 24279327 bps in 2024, then jumped 20943998 bps in 2025.
- Over 5 years, EBIT Margin stood at 2314.11% in 2022, then soared by 99 bps to 29.67% in 2023, then jumped by 376 bps to 81.84% in 2024, then declined by 10 bps to 73.45% in 2025, then surged by 513 bps to 450.39% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 450.39%, 73.45%, and 39769.22% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | InflaRx | 135.25 Mn | -49.00 Mn | 2.74 Bn | -17,899.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 450.39% |
| Dec 31, 2025 | 73.45% |
| Sep 30, 2025 | -39,769.22% |
| Jun 30, 2025 | -32,760.16% |
| Mar 31, 2025 | -36,088.30% |
| Dec 31, 2024 | 81.84% |
| Sep 30, 2024 | -12,405.24% |
| Jun 30, 2024 | -242,200.14% |
| Mar 31, 2024 | -34,655.19% |
| Dec 31, 2023 | -29.67% |
| Sep 30, 2023 | -0.02% |
| Jun 30, 2023 | 593.13% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | -2,314.11% |
| Sep 30, 2022 | 1,290.98% |
| Jun 30, 2022 | -7.31% |
| Mar 31, 2022 | 1,785.36% |
| Dec 31, 2021 | 0.20% |
| Sep 30, 2021 | 1,905.72% |
| Jun 30, 2021 | -100.00% |